Terminated PHASE2 INTERVENTIONAL 2-arm NCT00529503

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

A Randomized Phase IIb Placebo-controlled Study of R-ICE Chemotherapy With and Without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-line Treatment of Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Sponsor: Genentech, Inc.

Conditions Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin

Interventions SGN-40 carboplatin etoposide ifosfamide placebo rituximab

Updated 9 times since 2017 Last updated: Feb 6, 2015 Started: Sep 30, 2007 Primary completion: Dec 31, 2009 Completion: May 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Genentech, Inc.

More terminations from Genentech, Inc.

Other Lymphoma, Large B-Cell, Diffuse trials with similar outcome

Browse all Lymphoma, Large B-Cell, Diffuse trials

This PHASE2 trial investigates Lymphoma, Large B-Cell, Diffuse and Lymphoma, Non-Hodgkin and is currently terminated or withdrawn. Genentech, Inc. leads this study, which shows 9 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Apr 2022 [monthly]

Terminated PHASE2

▶ Show 4 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
Seagen Inc.

Data source: Seagen Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Barcelona, Spain , Birmingham, United States , Charleston, United States , Chicago, United States , Cleveland, United States , Columbus, United States , Dallas, United States , Darlinghurst, Australia , Debrecen, Hungary and 52 more locations